Steroid receptors in breast cancer

British Journal of Surgery

Volumn 78, Issue 5, 1991, Pages 528-535

  Rayter, Z ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN; STEROID RECEPTOR; TAMOXIFEN CITRATE; ZINC;

ASPIRATION BIOPSY; BREAST CANCER; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; BREAST NEOPLASMS; CELL NUCLEUS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; MENOPAUSE; MIDDLE AGE; PROGNOSIS; RECEPTORS, ESTRADIOL; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID;

EID: 0025732393     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.1800780506     Document Type: Review

References (164)

1. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation award lecture
2. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases
3. On oophorectomy in cancer of the breast
4. Proliferation, hormonal responsiveness and estrogen‐receptor content of MCF‐7 human breast cancer cells grown in the short‐term and long‐term absence of estrogen
5. A two‐step mechanism for the interaction of estradiol with rat uterus
6. New aspects of the molecular growth regulation of mammary tumours
7. Mechanisms of growth control in normal and malignant breast epithelium
8. Growth factors and cancer
9. Human breast carcinoma cells produce growth regulatory peptides
10. Definition of hormones and growth factors required for optimal proliferation and expression of phenotypic responses in human breast cancer cells
11. Purification and properties of a mammary‐uterine‐pituitary tumour cell growth factor from pregnant sheep uterus
12. Characterization of estrogen responsive transforming activity in human breast cancer cell lines
13. Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF‐7)
14. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
15. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma
16. Synthesis and secretion of platelet derived growth factor by human breast cancer cell lines
17. Induction of epidermal growth factor‐related polypeptides by 17 estradiol in human breast cancer cells
18. Receptors for epidermal growth factor and insulin‐like growth factor I and their relation to steroid receptors in human breast cancer
19. Epidermal and transforming growth factor‐a in patients with breast tumours
20. Growth factors: mechanism of action and relation to oncogenes
21. Stimulation of mammary carcinoma cell proliferation by epidermal growth factor in vitro
22. The role of protein kinase C in cell surface signal transduction and tumour promotion
23. Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF‐7)
24. Estrogen‐induced synthesis of a major intracellular protein in human breast cancer cells
25. The action of oestrogens and antioestrogens on cultured breast tumour cell lines
26. Effects of antiestrogens on the estrogen‐regulated p52 RNA and the 52‐ and 160‐kilodalton proteins in MCF‐7 cells and two tamoxifen‐resistant sublines
27. Cathepsin D: an independent prognostic factor for metastasis in breast cancer
28. Estrogen receptor interaction
29. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
30. Subunit composition of the molybdate‐stabilised ‘8‐9S’ nontransformed estradiol receptor purified from calf uterus
31. A 90000‐dalton binding protein common to both steroid receptors and the Rous sarcoma virus transforming protein p p 60vsrc
32. Conformational forms of the estrogen receptor
33. Characterisation of the subunit nature of nuclear estrogen receptors by chemical cross‐linking and dense amino acid labelling
34. Subunit composition of the estrogen receptor
35. The chicken oestrogen receptor sequence: homology with v‐erb A and the human oestrogen and glucocorticoid receptors
36. Human oestrogen receptor with DNA: sequence, expression and homology to v‐erb A
37. Primary structure and expression of a functional human glucocorticoid receptor with DNA
38. Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA
39. Cloning of the chicken progesterone receptor
40. Molecular cloning of the chicken progesterone receptor
41. Localisation of the oestradiol‐binding and putative DNA‐binding domains of the human oestrogen receptor
42. Functional domains of the human glucocorticoid receptor
43. Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid responsive element
44. Oestradiol induction of a glucocorticoid‐responsive gene by a chimaeric receptor
45. Repetitive zinc‐binding domains in the protein transcription factor IIIA from Xenopus oocytes
46. Sequence homology of the yeast regulatory protein ADR 1 with Xenopus transcription factor TFIIIA
47. Nuclear receptors enhance our understanding of transcription regulation
48. Genomic organization of the human oestrogen receptor gene
49. The N‐terminal DNA‐binding ‘zinc finger’ of the oestrogen and glucocorticoid receptors determines target gene specificity
50. Effects of steroids and their antagonists on breast cancer cells: therapeutic implications
51. Oestrogen receptor content of normal breast cells and breast carcinoma throughout the menstrual cycle
52. The involvement of oestrogen in the development and function of the normal human breast: histological evidence
53. Immunohistochemical expression of oestrogen receptor in normal breast tissue
54. Tumour cellularity, oestrogen receptors and prognosis in breast cancer
55. Tumour epithelial cellularity and quantitative oestrogen receptor values in primary breast cancer
56. Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer
57. Human breast carcinoma cells in continuous culture: a review
58. Characterization of estrogen receptor messenger RNA in human breast cancer
59. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumours
60. Oestrogen‐induced increase of oestrogen receptor RNA in human breast cancer cells
61. Estrogen control of progesterone receptor in human breast cancer
62. Molecular and cellular biology of mammalian progesterone receptors
63. Human progesterone A‐receptors can be synthesized intracellularly and are biologically functional
64. Transforming capacities of avian erythroblastosis virus mutants deleted in the erb A or erb B oncogenes
65. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A 431 epidermoid carcinoma cells
66. Epidermal growth factor receptors and oestrogen receptors in human breast cancers
67. Improved sensitivity in the measurement of estrogen receptor in human breast cancer
68. The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy
69. An immunocytochemical method for demonstrating oestrogen receptor in human uterus using monoclonal antibodies to human estrophilin
70. Immunocytochemical localization of estrogen receptor in human breast tissue
71. Immunocytochemical assay for oestrogen receptor in fine needle aspirates of breast cancer by video image analysis
72. Determination of oestrogen receptors with monoclonal antibodies in fine needle aspirates of breast carcinoma
73. Determination of estrogen receptor in breast cancer using monoclonal antibody technology: result of a multicentre study in the United States
74. Frequency and distribution of estrogen receptor‐positive cells in normal, non‐lactating human breast tissue
75. Epidermal growth factor receptor and oestrogen receptors in the non‐malignant part of the cancerous breast
76. Estrogen receptor values in patients with benign breast disease
77. Estrogen and progesterone receptors in benign breast tumours and lesions: relationship with histological and cytological features
78. Menstrual cycle‐dependent variations of breast cyst fluid proteins and sex steroid receptors in the normal human breast
79. Progesterone receptors in breast fibroadenomas
80. Steroid receptor assay and prognosis
81. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients
82. Influence of endocrine status on bichemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients
83. Risk actors for breast cancer by oestrogen receptor status: a population‐based case‐control study
84. Pathologic findings from the National Surgical Adjuvant Breast Project. Correlations with concordant and discordant estrogen and progesterone receptors
85. Pathological review of breast lesions analyzed for estrogen receptor protein
86. Progesterone and estrogen receptors as prognostic variables in breast cancer
87. A correlation between oestrogen receptors and tumour size in primary breast cancer
88. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients
89. The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast
90. Association of oestrogen 116. receptors with parenchymal pattern at mammography
91. Multiple estrogen receptor assays in human breast cancer
92. Distribution of oestrogen and progesterone receptors on primary and lymph nodes in individual patients with breast cancer
93. Variability of steroid receptors in multiple biopsies of breast cancer: effect of systemic therapy
94. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after first recurrence
95. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases
96. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer
97. Correlation of primary breast cancer histopathology and estrogen receptor content
98. Histological grade and steroid receptor content of primary breast cancer ‐ impact on prognosis and possible modes of action
99. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (Nolvadex) trial
100. Immuno‐histochemical determination of estrogen and progesterone receptors in human breast carcinoma
101. Oestrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers
102. Factors influencing the estimation of oestrogen receptors in human malignant breast tumours
103. Oestrogen receptors and breast cancer: current status
104. Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay
105. Specific estrogen binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans
106. Tumour epithelial cellularity and quantitative oestrogen receptor values in primary breast cancer
107. Breast carcinoma cellularity and its relation to oestrogen receptor content
108. Malignant and benign mammary disease: estrogen binding in relation to clinical data
109. Oestrogen receptors, cellularity, elastosis and menstrual status in human breast cancer
110. Oestrogen receptors, lactate dehydrogenase and cellularity in human breast cancer
111. Prognostic value of DNA ploidy and S‐phase fraction in relation to oestrogen receptor content and clinicopathological variables in primary breast cancer
112. Relationship of How cytometry results to clinical and steroid receptor status in human breast cancer
113. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication
114. Ki 67 immunostaining in primary breast cancer: pathological and clinical associations
115. DNA flow cytometry in primary breast carcinoma
116. The influence of age on the DNA ploidy levels of breast tumours
117. Predictive power of progesterone receptor status in early breast carcinoma
118. Prognostic significance of oestrogen and progesterone receptor activities in breast cancer
119. Prognostic value of estrogen and progesterone receptors in operable breast cancer
120. Survival with breast cancer: the importance of estrogen receptor quantity
121. Disease free interval and estrogen receptor activity in tumour tissue of patients with primary breast cancer: analysis after long‐term follow up
122. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer
123. Prognostic significance of estrogen receptor status in breast cancer in relation to tumour stage, axillary node metastases and histological grading
124. Estrogen receptor quantification and staging as complementary prognosis indicators in breast cancer. A study of 583 patients
125. Progesterone and estrogen receptors as prognostic variables in breast cancer
126. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease
127. Steroid receptors and prognosis in operable (stage I and II) breast cancer
128. Role of steroid hormone receptors as prognostic factors in primary breast cancer
129. The influence of hormone receptors and hormonal adjuvant therapy on disease free survival in breast cancer: a multifactorial analysis
130. Confirmation of a prognostic index in primary breast cancer
131. Significance of estrogen and progesterone receptors, disease‐free interval and site of first metastasis on survival of breast cancer patients
132. Influence of S‐phase fraction on metastatic pattern and post‐recurrence survival in a randomized mammography screening trial
133. Prognostic factors in breast cancer and the development of a prognostic index
134. Analysis of c‐erb B‐2 expression in breast carcinomas with clinical follow‐up
135. Independent prognostic value of laminin receptor expression in breast cancer survival
136. Prognostic implication of estrogen receptor content in breast cancer
137. Steroid hormone receptors and survival after first relapse in breast cancer
138. Prognostic indicators in patients with isolated locoregional recurrence of breast cancer
139. Oestrogen receptors and prognosis in early breast cancer
140. Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer
141. Relationship between primary breast tumour receptor status and patient survival
142. Prognostic value of estrogen and progesterone receptors in primary breast cancer
143. Who needs steroid receptor assays?
144. Prognostic value of nuclear DNA content in breast cancer in relation to tumour size, nodal status, and estrogen receptor content
145. The influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastases
146. Clinical response and survival according to oestrogen receptor levels after bilateral ovari‐ectomy in advanced breast cancer
147. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen
148. Estrogen receptors and hormone dependence of breast cancer
149. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
150. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer
151. Progesterone receptors and human breast cancer
152. Predicting response to endocrine therapy in human breast cancer: a hypothesis
153. Receptors in the management of breast cancer
154. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer
155. Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial
156. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor levels
157. Randomized trial of chemo‐endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases
158. Antiestrogen‐cytotoxic chemotherapy and bacillus Calmette‐Guerin vaccination in stage II breast cancer: seventy‐two month follow‐up
159. Premenopausal breast cancer adjuvant chemotherapy ‐ the Eastern Cooperative Oncology Group Trial
160. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐positive tumours
161. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐negative tumours
162. The treatment of advanced breast cancer
163. Primary medical treatment in breast cancer